Flag of the European Union EU Clinical Trials Register Help

Clinical trials for lofarma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: lofarma. Displaying page 1 of 1.
    EudraCT Number: 2012-001651-39 Sponsor Protocol Number: BIGRADE-IHR-12 Start Date*: 2012-11-14
    Sponsor Name:LOFARMA
    Full Title: In-vivo biological standardization of Dermatophagoides, Betulaceae and Graminaceae extracts for the determination of the biological activity in HEP units
    Medical condition: Respiratory allergopathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10054928 Allergy to plants PT
    14.1 10021428 - Immune system disorders 10001742 Allergy to animal PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004522-10 Sponsor Protocol Number: Lais-Amb-11 Start Date*: 2012-05-06
    Sponsor Name:LOFARMA
    Full Title: Study on the efficacy and safety of three different doses of Lais Ambrosia tablets in patients with allergic rhinoconjunctivitis to pollen of Ambrosia
    Medical condition: rhinoconjunctivitis allergic to ragweed pollen
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10054928 Allergy to plants PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004472-35 Sponsor Protocol Number: DE_LODRO_GR19 Start Date*: 2019-02-26
    Sponsor Name:Lofarma S.p.A.
    Full Title: A single arm, open label, dose-escalation study of carbamylated monomeric grass pollen drops in patients with a history of allergic rhinoconjunctivitis
    Medical condition: Graminacee pollen induced allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10001738 Allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001822-89 Sponsor Protocol Number: SMART_1_2012 Start Date*: 2012-08-21
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Dose Finding Study of the Efficacy of LAIS® Birch-Alder tablets in patients suffering from tree pollen-induced allergic rhinoconjunctivitis
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003058-26 Sponsor Protocol Number: ModAll-Der/07 Start Date*: 2007-07-17
    Sponsor Name:LOFARMA
    Full Title: Pilot study on tolerability of specific immunotherapywith injective allergoid adsorbed on calcium phosphate in patients with respiratory allergy to house dust mite.
    Medical condition: allergic rhinoconjunctivitis with or without asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039085 Rhinitis allergic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003063-34 Sponsor Protocol Number: GSDL_DE_17 Start Date*: 2017-12-11
    Sponsor Name:Lofarma S.p.A.
    Full Title: A double-blind, placebo-controlled dose-escalation study of carbamylated monomeric tree pollen drops in patients with a history of allergic rhinoconjunctivitis.
    Medical condition: Treatment of tree pollen-induced allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002174-23 Sponsor Protocol Number: SMART_5 Start Date*: 2011-11-21
    Sponsor Name:Lofarma S.p.A.
    Full Title: A dose Finding Study of the Efficacy of LAIS Grass tablets in patients suffering from grass pollen-induced allergic rhinoconjunctivitis
    Medical condition: allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-005079-21 Sponsor Protocol Number: LOTAB_2b_HDM Start Date*: 2018-08-23
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Prospective, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Phase-II Study for the Efficacy and Safety of LAIS® House Dust Mites Sublingual Tablets in Patients with Mite-Induced Alle...
    Medical condition: Patients Suffering from Mite-Induced Allergic Rhino-Conjunctivitis Without or With Controlled Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000617-20 Sponsor Protocol Number: SMART_2 Start Date*: 2013-08-23
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Dose Finding Study of the Efficacy of LAIS® Mites Sublingual tablets in patients suffering from house dust mite-induced allergic rhinoconjunctivitis A prospective, double-blind, placebo-controlle...
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004916-79 Sponsor Protocol Number: SMART_10 Start Date*: 2013-02-26
    Sponsor Name:Lofarma S.p.A.
    Full Title: Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS® Grass tablets for patients with grass pollen-induced allergic rhinoconjunctivitis, a phase III study
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004431-38 Sponsor Protocol Number: Lais-Ragweed-15-16 Start Date*: 2015-03-05
    Sponsor Name:Lofarma S.p.A.
    Full Title: Double-blind, placebo-controlled, parallel-group, randomized multicentre study to assess the efficacy and safety of LAIS® Ragweed Sublingual tablet in patients with allergic rhinoconjunctivitis to ...
    Medical condition: Patients with allergic rhinoconjunctivities to ragweed pollen with or without asthma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004214-96 Sponsor Protocol Number: MEIN/15/Bil-PSR/002 Start Date*: 2017-02-02
    Sponsor Name:MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA
    Full Title: Bilastine and inflammation: an explorative study in subjects affected by Parietaria J.-induced Rhinoconjunctivitis – The Bi-FLO study
    Medical condition: Rhinoconjunctivitis induced by Parietaria J.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002129-43 Sponsor Protocol Number: SMART_7 Start Date*: 2013-12-09
    Sponsor Name:Lofarma S.p.A.
    Full Title: Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS®Birch-Alder tablets for patients with tree pollen-induced allergic rhinoconjunctivitis A Phase III study
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001532-65 Sponsor Protocol Number: LGT03-19 Start Date*: 2019-09-12
    Sponsor Name:LOFARMA S.P.A.
    Full Title: A prospective, multicenter, double-blind, placebo-controlled randomized study to assess efficacy and safety of LAIS® Grass pollen tablets in patients with seasonal grass pollen-induced allergic rhi...
    Medical condition: seasonal grass pollen-induced allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10036019 Pollen allergy LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002596-18 Sponsor Protocol Number: Lais-Birch-Alder-18-19 Start Date*: 2018-10-12
    Sponsor Name:LOFARMA S.P.A.
    Full Title: Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS Birch tablets for patients with tree pollen-induced allergic rhinoconjunctivitis with or without mild controlled asthma
    Medical condition: Tree pollen-induced allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004870 10036019 Pollen allergy LLT
    20.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007657-12 Sponsor Protocol Number: ParLais/09 Start Date*: 2009-10-26
    Sponsor Name:LOFARMA
    Full Title: Evaluating the efficacy, safety, tolerability of use and treatment adherence in two different dosing schedules, pre-costagionale and costagionale, of a sublingual allergoid (Lais Parietaria)adminis...
    Medical condition: Subjects with Parietaria pollen allergy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013923-43 Sponsor Protocol Number: Nichel-SNAS/09 Start Date*: 2010-03-03
    Sponsor Name:LOFARMA
    Full Title: Studio in doppio cieco controllato con placebo sulla efficacia e tollerabilita' della terapia desensibilizzante con nichel in pazienti affetti da sindrome sistemica da allergia al nichel
    Medical condition: Pazienti affetti da SNAS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046736 HLT
    9.1 10017926 HLT
    9.1 10013949 HLT
    9.1 10028817 HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 06:10:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA